1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

In July 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

BACKGROUND Bleeding is a potential complication after neuraxial and peripheral nerve
blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

This consensus document is proposed to clinicians to provide the whole spectrum of deep
vein thrombosis management as an update to the 2017 consensus document. New data …